6-(对甲苯)烟酸 | 521074-77-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(对甲苯)烟酸
• 英文名称: 6-(4-methylphenyl)nicotinic acid
• 英文别名: 6-(p-Tolyl)nicotinic acid；6-(4-methylphenyl)pyridine-3-carboxylic acid
• CAS: 521074-77-1
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: SBZIVZCDYSNVSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-(对甲苯)烟酸 在 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  基于磺酰胺的非炔烃LpxC抑制剂作为革兰氏阴性抗菌剂

  摘要：

  我们试图通过专注于酶抑制和抗菌活性的改善来优化基于磺酰胺的非炔烃LpxC抑制剂。发现具有2-芳基苯并呋喃作为疏水物的抑制剂表现出良好的活性。尤其是，化合物21显示出令人印象深刻的抗菌活性（大肠杆菌MIC = 0.063μg/ mL，肺炎克雷伯菌MIC = 0.5μg/ mL，铜绿假单胞菌MIC = 0.5μg/ mL），是进一步探索的有希望的先导作为抗菌剂。

  DOI：

  10.1016/j.bmcl.2016.12.059
• 作为产物：
  描述：

  6-氯烟酸 、 4-甲苯硼酸 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex tritylchloride-polystyrene resin 、 N,N-二异丙基乙胺 、 potassium phosphate 、 2-(phospha-adamantyl)benzene 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 四氢呋喃 、 水 为溶剂， 反应 34.5h， 生成 6-(对甲苯)烟酸
  参考文献：
  名称：

  Solid-phase Suzuki cross-coupling reactions using a phosphine ligand based on a phospha-adamantane framework

  摘要：

  The use of a catalyst system based on Pd(2)dba(3.)CHCl(3) and 1,3,5,7-tetramethyl-2,4,8-trioxa-6-phenyl-6-phosphaadamantane allows for Suzuki coupling aryl halides with an array of boronic acids on a solid-phase platform. The reactions can be carried out at room temperature with low palladium loadings in high yields. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.05.110

文献信息

• Melanin-concentrating hormone antagonist
  申请人：——

  公开号：US20030158177A1

  公开（公告）日：2003-08-21

  A melanin-concentrating hormone antagonist comprising a compound of the formula: 1 wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R 1 and R 2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R 1 and R 2 , together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R 2 , together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

  一种黑素浓缩激素拮抗剂，包括以下结构的化合物：其中R是氢原子或可能被取代的环状基团；X是具有1到10个原子主链的键或间隔物；Y是具有1到6个原子主链的间隔物；环A是苯环，可能进一步被取代；环B是一个含氮的非芳香杂环环，成员数为5到9，可能进一步被取代；R1和R2相同或不同，是氢原子、可能被取代的烃基或可能被取代的杂环基；或者R1和R2，与相邻的氮原子一起，可以形成一个可能被取代的含氮杂环环；或者R2，与相邻的氮原子和Y一起，可以形成一个可能被取代的含氮杂环环；或其盐可用作肥胖等疾病的预防或治疗剂。
• Quinoline compound
  申请人：Ishihara Yuji

  公开号：US20050209213A1

  公开（公告）日：2005-09-22

  A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Ar is a cyclic group optionally having substituent(s); X is a bond or a spacer having a main chain of 1 to 6 atoms; R 1 and R 2 are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R 1 and R 2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Y is a divalent hydrocarbon group optionally having substituent(s) (except CO); R 3 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring B may further have substituents, and when ring B further has a substituent, the substituent may be linked to R 1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

  一种化合物，具有黑色素浓缩激素拮抗作用，可用作预防或治疗肥胖症的药物，其化学式为：其中，Ar是一个环状基团，可以有取代基；X是1到6个原子的主链的键或空隙；R1和R2相同或不同，分别是氢原子或烃基，可以有取代基，或者R1和R2可以与相邻的氮原子一起形成含氮杂环，可以有取代基；Y是一个双价的烃基，可以有取代基（除CO）；R3是氢原子或烃基，可以有取代基；环A和环B还可以有取代基，当环B还有取代基时，取代基可以与R1连接形成一个环，或其盐，或其前药。
• MELANIN-CONCENTRATING HORMONE ANTAGONIST
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1283199A1

  公开（公告）日：2003-02-12

  A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

  一种黑色素浓缩激素拮抗剂，包括式中化合物： 其中 R 是氢原子或可被取代的环状基团；X 是主链为 1 至 10 个原子的键或间隔物；Y 是主链为 1 至 6 个原子的间隔物；环 A 是可被进一步取代的苯环；环 B 是可被进一步取代的 5 至 9 元含氮非芳香杂环；R1和R2相同或不同，且为氢原子、可被取代的烃基或可被取代的杂环基；或R1和R2连同相邻的氮原子可形成可被取代的含氮杂环；或R2连同相邻的氮原子和Y可形成可被取代的含氮杂环；或其盐可用作肥胖症等的预防或治疗剂。
• QUINOLINE COMPOUND
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1447402A1

  公开（公告）日：2004-08-18

  A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula:    wherein Aris a cyclic group optionally having substituent(s) ; Xis a bond or a spacer having a main chain of 1 to 6 atoms; R1 and R2are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Yis a divalent hydrocarbon group optionally having substituent(s) (except CO); R3is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring Bmay further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

  一种化合物，具有拮抗黑色素浓缩激素的作用，可作为预防或治疗肥胖症的药物，由式表示： 式中 Ar 是一个环状基团，可选择具有取代基； X 是主链为 1 至 6 个原子的键或间隔物； R1 和 R2 相同或不同，各自为氢原子或任选具有取代基的烃基，或 R1 和 R2 可与邻近的氮原子一起形成任选具有取代基的含氮杂环； Y 是可选具有取代基的二价烃基（CO 除外）； R3 是氢原子或可选具有取代基的烃基；以及 环 A 和环 B 可进一步具有取代基，当环 B 进一步具有取代基时，该取代基可与 R1 连接形成一个环、 或其盐或其原药。
• Melanin-Concentrating Hormone Receptor 1 Antagonists. Synthesis and Structure–Activity Relationships of Novel 3-(Aminomethyl)quinolines
  作者：Makoto Kamata、Toshiro Yamashita、Toshihiro Imaeda、Toshio Tanaka、Shinichi Masada、Masahiro Kamaura、Shizuo Kasai、Ryoma Hara、Shigekazu Sasaki、Shiro Takekawa、Asano Asami、Tomoko Kaisho、Nobuhiro Suzuki、Shuntaro Ashina、Hitomi Ogino、Yoshihide Nakano、Yasutaka Nagisa、Koki Kato、Kaneyoshi Kato、Yuji Ishihara

  DOI：10.1021/jm201596h

  日期：2012.3.8

  It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.